Get Access to Neratinib in India

Neratinib is approved for the treatment of Breast Cancer in specific settings. As per the FDA approvals, this is a targeted therapy drug that acts as Tyrosine Kinase Inhibitor. Its mechanism of action is unique. The dual blockade of HER and EGFR makes Neratinib unique and effective in the management of HER2 Positive Breast Cancer. Nerlynx is the brand name and Puma Biotechnology is licensed to promote this drug since 2011.

This advanced medication has received its US FDA approval in 2017 and EU EMA nod in 2018. This is now considered as an emerging option as an extended adjuvant treatment. Patients who received prior adjuvant therapy with trastuzumab are ideally recommended on this medication. In February 2020, FDA has approved Nerlynx for the treatment of metastatic HER2 Positive Breast Cancer. Neratinib in India has a clear role to play. Nerlynx in India can be imported through NPS channels.

Commercially Nerlynx 40mg tablets are available in a pack of 180 tablets. This drug is predominantly available and accessible from the US and European countries. In case of Indian scenario, the oncologists treating Breast Cancer patients prefer to extend all the possible options available. By nature of disease and with the available therapeutic advancements, Breast Cancer patients are often considered to have better survival possibilities. Advanced options like Nerlynx will expand this scope